Last updated: August 10, 2026
Quick answer: The FDA granted accelerated approval to Replimune’s Tudriqev (vusolimogene oderparepvec-wtpg) on August 6, 2026, in combination with nivolumab for advanced cutaneous melanoma that progressed on anti PD-1 therapy. The approval followed two prior rejections and a 10 to 3 advisory committee vote against the agency’s own reviewers. Separately, Curium agreed to acquire Lantheus for up to $8.0 billion in one of three infrastructure deals landing in the same stretch.
This reference page covers the Replimune regulatory timeline, the IGNYTE trial data, what accelerated approval requires, the Curium and Lantheus deal terms, and the wider infrastructure acquisition wave.
What did the FDA approve for Replimune?
The FDA granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg), previously known as RP1, in combination with nivolumab, for adults with unresectable advanced cutaneous melanoma who experienced disease progression on an anti PD-1 antibody based regimen. Approval came on August 6, 2026.
Tudriqev is a genetically modified oncolytic herpes simplex virus injected directly into tumors. Once inside, it replicates and destroys cancer cells, which then release proteins that stimulate a broader immune response against the tumor.
The IGNYTE trial data
| Measure | Result |
|---|---|
| Patients enrolled | 140 |
| Efficacy evaluable population | 91 |
| Objective response rate | 24.2% |
| Median duration of response | 14.1 months |
| Basis of approval | Objective response rate and duration of response |
| Confirmatory trial | Required |
| Designations | Breakthrough Therapy, Priority Review |
The efficacy evaluable group consisted of patients with at least one non injected lesion, which allows assessment of whether the therapy produces responses beyond the tumors directly treated.
Why was Replimune rejected twice before approval?
Both prior rejections centered on the single arm design of the IGNYTE trial. Because every patient received Tudriqev together with nivolumab, and no control arm received nivolumab alone, regulators argued it was not possible to determine how much of the observed effect came from Tudriqev itself.
The full regulatory timeline
| Stage | Outcome |
|---|---|
| First submission | Rejected. Single arm design cited. |
| Second submission | Rejected. Same methodological objection. |
| Public dispute | Then FDA commissioner Marty Makary publicly defended the rejections. The case became a focal point in industry criticism of the agency. |
| Leadership change | Following Makary’s departure, Replimune negotiated a path forward with the agency. |
| Third submission, June 2026 | Accepted, with the FDA committing to a compressed review schedule. |
| Late July 2026 | FDA reviewers released briefing documents describing the data package as not interpretable. Replimune shares fell roughly a third. |
| July 30, 2026 | Cellular, Tissue and Gene Therapies Advisory Committee voted 10 to 3 that the results were clinically meaningful. |
| August 6, 2026 | FDA granted accelerated approval. |
The three dissenting panelists maintained the objection about isolating the drug’s individual contribution. The majority concluded the response signal was strong enough to support approval in a population with few remaining options, and noted that the pending confirmatory trial could resolve the question relatively quickly.
The FDA’s approval announcement explicitly cited input from clinical experts and patient advocates who emphasized the urgency of new options for this refractory group.
What does accelerated approval mean for Tudriqev?
Accelerated approval permits the FDA to clear a drug based on a surrogate or intermediate endpoint reasonably likely to predict clinical benefit, rather than on direct evidence of improved survival. For Tudriqev, the endpoints were objective response rate and duration of response.
The approval is conditional. Replimune is required to conduct post approval trials to verify and describe clinical benefit, and continued approval may depend on those results. An ongoing Phase 3 trial serves that purpose. If it fails to confirm benefit, the approval can be withdrawn.
Practical implication: Tudriqev is commercially available now, but the Phase 3 readout remains a genuine binary event for Replimune, and the approval carries a condition that a standard approval would not.
How much does Tudriqev cost?
Reporting from STAT News places the list price at $450,000 for a full course of treatment, before rebates and discounts. Replimune has not confirmed a price publicly in its announcement materials. Patients prescribed the therapy have access to ReplimuneConnect Plus, the company’s access, reimbursement, and financial support program.
What is the Curium and Lantheus deal?
Curium agreed to acquire Lantheus Holdings in a transaction valued at up to approximately $8.0 billion. The agreement was announced August 3, 2026 and unanimously approved by Lantheus’s board.
Deal terms
| Component | Detail |
|---|---|
| Cash at closing | $102.50 per share |
| Contingent value rights | Up to $12.00 per share |
| Total per share consideration | Up to $114.50 |
| Aggregate transaction value | Up to approximately $8.0 billion |
| Premium to unaffected 60 day VWAP | 38% |
| Premium to unaffected 30 day VWAP | 29% |
| Expected close | First half of 2027 |
| Post close status | Lantheus becomes privately held |
How the contingent value rights break down
| Milestone | Maximum value |
|---|---|
| Prostate cancer diagnostics sales milestones | Up to $8.00 per share |
| Neurology diagnostics sales milestones | Up to $3.00 per share |
| DEFINITY exceeding $400 million in sales in FY2030 | $1.00 per share |
There is no guarantee any contingent payment will be earned. Lantheus has suspended its previously issued full year 2026 guidance because of the pending transaction. The company reported second quarter 2026 worldwide revenue of $388.2 million.
Why Curium bought a diagnostics company
Curium is a radiopharmaceutical company backed by CapVest Partners, employing more than 3,800 people across over 80 manufacturing sites. Lantheus’s lead product is Pylarify, a PET imaging agent used in prostate cancer.
The strategic logic runs through eligibility. Radioligand therapies such as Pluvicto are prescribed to patients whose tumors are confirmed by imaging to express the relevant target. The diagnostic determines who qualifies for the therapy. By acquiring Lantheus, Curium acquired the imaging step that gates access to treatment, rather than acquiring another competing therapy.
The combined company would span radiodiagnostics and theranostics, serving oncology, neurology, and cardiology patients across more than 70 countries.
Why are investors buying biotech infrastructure instead of drugs?
Three infrastructure transactions landed in the same stretch, all targeting the layer beneath drug development rather than drugs themselves.
| Acquirer | Target | Value | Segment |
|---|---|---|---|
| Curium | Lantheus | Up to $8.0 billion | Radiodiagnostics and theranostics |
| Nordic Capital | BWXT medical isotope business | Up to $800 million | Medical isotope supply |
| KKR | Integer | Not disclosed here | Medtech contract manufacturing |
The underlying thesis is that infrastructure captures value with less binary risk than therapeutic development. An individual drug program either succeeds or fails, and most fail. Companies supplying isotopes, manufacturing capacity, and diagnostics generate revenue across the entire field regardless of which specific molecules succeed.
Radioligand therapy illustrates the point. It is among oncology’s fastest growing modalities, but it depends on a supply chain that is difficult to build: isotope production, logistics constrained by short radioactive half lives, and specialized manufacturing. Those constraints create durable competitive positions.
Related transactions from the preceding weeks: Samsung Biologics agreed to acquire PolyPeptide for $1.8 billion to expand peptide manufacturing capacity serving GLP-1 demand, and Repligen agreed to acquire BioLife for $1.5 billion for cell therapy inputs. Merck KGaA’s $11.3 billion acquisition of Bio-Techne earlier in 2026 followed similar logic in research reagents.
What else happened, August 6 to 9, 2026
Tarsus to acquire Alkeus Pharmaceuticals
Tarsus Pharmaceuticals entered a definitive agreement to acquire Alkeus Pharmaceuticals, a privately held retinal disease company developing gildeuretinol (ALK-001), an investigational once daily oral therapy for Stargardt disease. Stargardt is an inherited retinal disorder causing progressive central vision loss, typically beginning in childhood or adolescence, with no approved treatment.
Moderna’s mRNA flu vaccine cleared
Moderna’s mRNA based seasonal influenza vaccine was cleared, making it the first preventive influenza vaccine built on mRNA technology. The significance extends beyond the product: COVID vaccines demonstrated the platform in an emergency setting, while a seasonal flu vaccine demonstrates it can compete in a routine, established commercial market. It also makes combination respiratory vaccines a more realistic prospect.
Biotech IPOs pass $6 billion
Drug startups have raised $6 billion through initial public offerings in 2026, exceeding the combined total raised by this point across the previous four years. Five additional biotechnology companies were positioned to price offerings, potentially raising more than $1 billion collectively.
The concentration caveat persists. Companies reaching public markets are disproportionately those with clinical stage assets. Approximately two thirds of venture rounds in the first half of 2026 went to companies that already had a drug in human testing, leaving preclinical companies facing the tightest conditions in years.
TransThera wins Chinese approval in cholangiocarcinoma
TransThera Sciences’ Yochanra (tinengotinib) was approved in China for adults with advanced, metastatic, or unresectable cholangiocarcinoma harboring a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement, who previously received systemic therapy and FGFR inhibitor treatment. Cholangiocarcinoma is an aggressive bile duct cancer with limited treatment options, and the post FGFR inhibitor setting is narrower still.
Additional developments
- Biocon commercially launched Yesafili (aflibercept-jbvf) in the United States, adding biosimilar competition in ophthalmology.
- Revolution Medicines rose after early indicators from a compassionate use program prompted analysts to raise projections for daraxonrasib, its pan RAS inhibitor.
- Intellia indicated it has addressed a key safety question, and Arrowhead moved to close ground on a rival.
- Jennifer Taubert is stepping down after a lengthy run leading Johnson & Johnson’s pharmaceutical business.
- Evotec entered a research and development collaboration with Odyssey Therapeutics to discover small molecule candidates for autoimmune and inflammatory diseases.
- Ensoma cut jobs and narrowed its focus to its lead asset.
- Novo Nordisk’s chief financial officer characterized the company’s financial year as a roller coaster in an interview timed to second quarter results.
- National Pharmacy Association analysis found medicines wasted in England last year could have filled roughly 75 swimming pools.
Frequently asked questions
What is Tudriqev?
Tudriqev (vusolimogene oderparepvec-wtpg), previously known as RP1, is a genetically modified oncolytic herpes simplex virus developed by Replimune. It is injected directly into tumors, where it replicates and destroys cancer cells while triggering an immune response. It received FDA accelerated approval on August 6, 2026.
What is Tudriqev approved for?
Tudriqev is approved in combination with nivolumab for adults with unresectable advanced cutaneous melanoma who experienced disease progression on an anti PD-1 antibody based regimen.
How effective is Tudriqev?
In the IGNYTE trial, 91 efficacy evaluable patients showed a 24.2% objective response rate with a median duration of response of 14.1 months.
Why was Replimune rejected by the FDA twice?
Both rejections centered on the single arm design of the IGNYTE trial. Because all patients received Tudriqev together with nivolumab, with no arm receiving nivolumab alone, regulators argued the trial could not isolate how much of the effect was attributable to Tudriqev.
How did Replimune get approved after two rejections?
Following a change in FDA leadership, Replimune negotiated a path forward and submitted a third application in June 2026 under a compressed review. Despite FDA reviewers releasing critical briefing documents, an advisory committee voted 10 to 3 that the results were clinically meaningful, and the agency granted accelerated approval on August 6, 2026.
What was the Replimune advisory committee vote?
The Cellular, Tissue and Gene Therapies Advisory Committee voted 10 to 3 on July 30, 2026 that the trial results were clinically meaningful.
What does accelerated approval mean?
Accelerated approval allows the FDA to clear a drug based on a surrogate or intermediate endpoint reasonably likely to predict clinical benefit, rather than on direct evidence of improved survival. The company must conduct confirmatory trials, and continued approval may depend on those results.
How much does Tudriqev cost?
STAT News reported a list price of $450,000 for a full course of treatment, before rebates and discounts. Replimune has not publicly confirmed a price in its announcement materials.
How much is Curium paying for Lantheus?
Up to approximately $8.0 billion. Lantheus shareholders receive $102.50 per share in cash at closing plus contingent value rights worth up to $12.00 per share, for total consideration of up to $114.50 per share.
When will the Curium and Lantheus deal close?
The transaction is expected to close in the first half of 2027, subject to Lantheus shareholder approval and regulatory clearances. Lantheus will become privately held after closing.
What are the Lantheus contingent value rights tied to?
Prostate cancer diagnostics milestones worth up to $8.00 per share, neurology diagnostics milestones worth up to $3.00 per share, and $1.00 per share if the DEFINITY business exceeds $400 million in sales in fiscal year 2030.
Why did Curium buy Lantheus?
Lantheus’s lead product Pylarify is a PET imaging agent used to determine which prostate cancer patients qualify for radioligand therapy. Acquiring Lantheus gives Curium the diagnostic step that gates access to treatment, alongside a complementary US radiodiagnostics business.
What is Stargardt disease?
Stargardt disease is an inherited retinal disorder that causes progressive loss of central vision, typically beginning in childhood or adolescence. There is no approved treatment. Tarsus Pharmaceuticals agreed to acquire Alkeus Pharmaceuticals and its investigational once daily oral therapy gildeuretinol for the condition.
How much have biotech IPOs raised in 2026?
Drug startups have raised $6 billion through initial public offerings so far in 2026, more than the combined amount raised by this point across the previous four years.
Is there an mRNA flu vaccine?
Yes. Moderna’s mRNA based seasonal influenza vaccine was cleared, making it the first preventive flu shot built on mRNA technology.
Sources
Primary sources are named first where available.
- Replimune Tudriqev approval — US Food and Drug Administration press announcement, August 6, 2026; Replimune Group press release and SEC Form 8-K Exhibit 99.1, August 6, 2026; corroborated by BioPharma Dive and Quartz
- Tudriqev list price — STAT News, reported via Quartz, August 7, 2026. Not company confirmed.
- Curium and Lantheus transaction — Curium press release and Lantheus Holdings investor relations, August 3, 2026; Lantheus SEC Form 8-K, August 6, 2026; corroborated by CNBC and Fierce Biotech
- Lantheus Q2 2026 results — Lantheus Holdings SEC Form 8-K Exhibit 99.1, August 6, 2026
- Nordic Capital and BWXT, KKR and Integer — BioBucks M&A tracker, updated August 7, 2026
- Tarsus and Alkeus, TransThera Yochanra approval, Biocon Yesafili launch, Evotec and Odyssey, medicines waste analysis — The Pharma Letter, August 7 and 8, 2026
- Biotech IPO totals, Moderna mRNA flu clearance, Revolution Medicines, Intellia, Arrowhead, J&J leadership — BioPharma Dive, August 6 and 7, 2026
- Ensoma job cuts — BioSpace Layoff Tracker, August 7, 2026
- Novo Nordisk CFO interview — Fierce Biotech, August 7, 2026
Related BioMed Nexus coverage
- Retatrutide vs. CagriSema: Why 2026 is the Year of the Triple Agonist
- AstraZeneca and BMS Reportedly Weigh a $400B Merger
- Supernus and Indivior Are Merging Into a CNS Powerhouse
- 20 CDMOs Powering Cell and Gene Therapy Manufacturing in 2026
- The Biotech Infrastructure Stack: 50 Companies Powering Drug Development
BioMed Nexus delivers daily life sciences intelligence to executives, investors, and clinicians. The daily briefing carries the strategic read behind the developments that matter.
© 2026 BioMed Nexus. All rights reserved.
